Drug Development Pipeline
ACG-701 (formerly ARV-1801) is a version of sodium fusidate. It is a compound that is used to treat methicillin-resistant Staphylococcus aureus, a cause of some CF lung infections, and may also decrease inflammation and mucus production. Sodium fusidate has been used in Europe, but it has never been approved in the U.S. This potential treatment comes in oral tablet form.
A phase 2 study to test the safety and effectiveness of ACG-701 in people with CF is planned.
This program is sponsored by Aceragen and partially funded by the Cystic Fibrosis Foundation. Clinical trials will be conducted through the Therapeutics Development Network.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More